Market Place
Sourcing Support
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D. to Board
11 Mar 2025 //
ACCESSWIRE
Juvisé licenses J&J’s MS drug Ponvory for marketing outside North America
27 Mar 2024 //
PRESS RELEASE
Treatment with RYBREVANT and Lazertinib Showed Survival in Advanced NSCLC
11 Sep 2023 //
PR NEWSWIRE
EC grants CMA to Janssen`s Talvey for multiple myeloma
23 Aug 2023 //
PRESS RELEASE
Alkermes` $194M payment from Janssen gets approval from court
21 Aug 2023 //
ENDPTS
FDA approves J&J`s PARP combo drug Akeega for prostate cancer
12 Aug 2023 //
FDA
Erleada Approved as the Only Androgen Receptor Inhibitor in Canada
10 Aug 2023 //
NEWSWIRE
LianBio Partner NANOBIOTIX Enters into Agreement with Janssen for NBTXR3
18 Jul 2023 //
GLOBENEWSWIRE
FMF World Congress 2023: Janssen shares new data in HDFN
27 Jun 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
J&J touts PhII data in rare blood disorder as it plots a pivotal study
27 Jun 2023 //
ENDPTS
Janssen Submits MAA to EMA Seeking Approval of STCT of Macitentan & Tadalafil
26 Jun 2023 //
GLOBENEWSWIRE
Physicians rate Janssen, Merck & Novo Nordisk best for customer experience in US
21 Jun 2023 //
ENDPTS
Alkermes Announces Final Award in Janssen Arbitration
06 Jun 2023 //
PR NEWSWIRE
Janssen Announces Erdafitinib Improved Overall Survival Versus Chemotherapy
05 Jun 2023 //
GLOBENEWSWIRE
CARVYKTI Reduces Risk of Death by 74% in Earlier-Line Multiple Myeloma
05 Jun 2023 //
GLOBENEWSWIRE
Data from the CHRYSALIS Study Show Progression-Free Survival Not Reached
04 Jun 2023 //
GLOBENEWSWIRE
Janssen Presents First Results from Dual Bispecific Combination Study
03 Jun 2023 //
GLOBENEWSWIRE
Janssen Tremfya excels as psoriasis treatment, outshining IL-17s
01 Jun 2023 //
INDIAN PHARMA POST
Janssen Submits NDA to FDA Seeking Approval of Invg Single Tab ComboTherapy
30 May 2023 //
PR NEWSWIRE
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications
25 May 2023 //
PRESS RELEASE
Janssen reports decline in 2022 net prices as out-of-pocket costs grow
25 May 2023 //
ENPTS
Janssen Seeks European Commission Approval of a New Indication for CARVYKTI
25 May 2023 //
GLOBENEWSWIRE
Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial
10 May 2023 //
CLINICAL TRIALS ARENA
First Phase 3 TREMFYA® Data in Inflammatory Bowel Disease +Ve Results
09 May 2023 //
PR NEWSWIRE
J&J refuels CAR-T ambitions with $245M Cellular Biomedicine deal
02 May 2023 //
FIERCE BIOTECH
Janssen gets priority review for prostate cancer; ImmunoGen reports Q1 sales
28 Apr 2023 //
ENDPTS
China Approves Sales of Janssen’s Antidepressant
22 Apr 2023 //
YICAIGLOBAL
Janssen to Highlight Innovation in Retinal Pipeline at ARVO
21 Apr 2023 //
PR NEWSWIRE
NICE gives green light to ibrutinib plus venetoclax for lymphocytic leukaemia
21 Apr 2023 //
PHARMIWEB
Genmab Announces Initial Resolution of Its 2nd Arbitration Agreementwith Janssen
20 Apr 2023 //
GLOBENEWSWIRE
Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront
18 Apr 2023 //
ENDPTS
Erleada, First Next-Generation Androgen Receptor Inhibitor Available in U.S.
03 Apr 2023 //
PR NEWSWIRE
New RYBREVANT Data Showed Long-Term Clinical Response and Safety in Patients
29 Mar 2023 //
PR NEWSWIRE
Janssen announces dengue antiviral demonstrates efficacy in pre-clinical data
20 Mar 2023 //
INDIAN PHARMA POST
Janssen Announces Dengue Antiviral Shows Efficacy in Data Published in Nature
15 Mar 2023 //
BUSINESSWIRE
Biocytogen Announces RenLite™ Licensing Agreement with Janssen
08 Mar 2023 //
BUSINESSWIRE
Janssen Licenses Biocytogen`s RenLite Platform
08 Mar 2023 //
CONTRACT PHARMA
Protagonist`s story turns for the better on psoriasis data
08 Mar 2023 //
FIERCE BIOTECH
STELARA Data Support its Established Safety in Inflammatory Bowel Disease
04 Mar 2023 //
PR NEWSWIRE
BMS, J&J kick off pivotal studies of FXIa inhibitor milvexian
03 Mar 2023 //
PRESS RELEASE
The BMS-Janssen Collaboration Launches PIII Trial Evaluating Milvexian
02 Mar 2023 //
BUSINESSWIRE
Positive CHMP opinion for Janssen’s AKEEGA
27 Feb 2023 //
PHARMATIMES
Kura Oncology drops multiple clinical programs for J&J-discovered tipifarnib
24 Feb 2023 //
ENDPTS
J&J’s Janssen lays off employees at Pennsylvania, New Jersey sites
03 Feb 2023 //
ENDPTS
Evotec announces agreement with Janssen to develop immune-based therapies
27 Jan 2023 //
ENDPTS
Morphic loses second partner as J&J exits integrin alliance
24 Jan 2023 //
PHARMA PHORUM
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen
06 Jan 2023 //
GLOBENEWSWIRE
Janssen and ACS team up to promote patient navigation
04 Jan 2023 //
FIERCE PHARMA
Janssen gets help from Hero in reaching the Black community
22 Dec 2022 //
FIERCEPHARMA
Janssen Presents Efficacy Analyses from MAIA Study Showing Results of DARZALEX
12 Dec 2022 //
PRNEWSWIRE
Janssen peels back layer of data on its new myeloma bispecifc
12 Dec 2022 //
FIERCEBIOTECH
Janssen Presents Data from MajesTEC-2 Trial of TECVAYLI with DARZALEX
10 Dec 2022 //
GLOBENEWSWIRE
Results from PIII Study of Fixed-Duration Treatment with IMBRUVICA show Efficacy
10 Dec 2022 //
PRNEWSWIRE
Janssen Presents Data for Talquetamab Suggesting Durable Responses in Myeloma
10 Dec 2022 //
PRNEWSWIRE
Janssen Presents Data from MajesTEC-2 Trial of TECVAYLI with DARZALEX FASPRO
10 Dec 2022 //
PRNEWSWIRE
Janssen Submits BLA to U.S. FDA for Talquetamab for the Treatment of Patients
09 Dec 2022 //
PRNEWSWIRE
